Evvy, a women's health startup focused on vaginal microbiome research, has closed a $40 million Series B round led by Catalio Capital Management. The funding accelerates the company's mission to expand data collection and drive clinical research that addresses gaps in women's reproductive health.
Evvy operates a direct-to-consumer platform that collects vaginal microbiome samples from users, creating what the company frames as the largest longitudinal database of vaginal microbiome data outside of clinical settings. This dataset fuels research into conditions like bacterial vaginosis, yeast infections, and infertility, areas historically underfunded and understudied relative to other medical fields.
The company's model combines consumer engagement with research partnerships. Evvy users submit samples and health data through its app, then the company sequences and analyzes that genetic material. Researchers, pharma companies, and diagnostics firms access anonymized data to advance understanding of vaginal health conditions and develop new treatments or diagnostics.
Catalio Capital's lead demonstrates growing institutional confidence in women's health technology. The venture firm focuses on life sciences and healthcare investments, signaling that Evvy's approach to women's reproductive health data resonates with serious capital. Series B rounds of this size indicate the company has demonstrated traction in user acquisition, data quality, and partnership revenue.
The funding round comes as women's health tech attracts broader venture attention. Companies like Ro, Modern Fertility, and Nurx have raised substantial capital by addressing contraception, fertility tracking, and hormone therapy distribution. Yet the microbiome space remains less crowded. Evvy competes with academic institutions and traditional clinical research organizations for data and partnerships, but faces fewer direct venture-backed competitors in the vaginal microbiome segment.
The capital infusion enables Evvy to expand its user base, recruit more research participants, and deepen partnerships with pharmaceutical companies developing vaginal health treatments. Larger datasets strengthen the company's competitive moat. Pharmaceutical firms increasingly rely on real-world evidence and consumer data to inform drug development. Evvy's growing database becomes more valuable as it ages, allowing researchers to track microbiome changes over years rather than months.
Regulatory pathways matter here too. Evvy operates as a research platform rather than a diagnostic service, which sidesteps certain FDA oversight. However, the company must navigate data privacy regulations and genetic testing regulations carefully. HIPAA compliance and state-by-state genetic testing laws constrain how Evvy collects, stores, and shares microbiome data.
The Series B also signals confidence in the broader premise that consumer-generated health data, properly anonymized and managed, can accelerate clinical research. This model differs from traditional pharma trials, which rely on smaller, often less diverse patient populations. A dataset built from thousands of app users across different geographies and demographics offers research advantages that legacy clinical models cannot match.
Evvy's path to revenue likely involves partnerships with biotech companies developing vaginal health therapies, diagnostic licensing agreements, and potential B2B offerings to healthcare providers. The company has not disclosed current revenue but the Series B round suggests investors believe the team can monetize its data moat and research relationships at scale.